接受器对抗β细胞中的胰岛素信号,以控制血糖
Ansarullah1,2, Chirag Jain1,2, Fataneh Fathi Far1,3
1Institute of Diabetes and Regeneration Research, Helmholtz Center Munich, Neuherberg, Germany.
Nature
|January 28, 2021
概括
研究人员发现了一种新的蛋白质, 阻断受体增强胰岛素受体活性,可能为糖尿病治疗提供新的治疗点.
科学领域:
- 内分泌学
- 分子生物学
- 细胞生物学
背景情况:
- 胰腺β细胞对胰岛素和IGF1的抵抗导致糖尿病.
- 能使β细胞对胰岛素敏感的疗法可以防止β细胞衰竭.
- 了解β细胞信号对于治疗糖尿病至关重要.
研究的目的:
- 在胰腺β细胞中识别胰岛素和IGF1受体信号的新调节剂.
- 研究胰岛素抑制受体 (受体) 在β细胞功能和发育中的作用.
- 作为糖尿病的潜在治疗点.
主要方法:
- 产生和分析受体淘汰 (Iir-/-) 鼠.
- 胰腺组织和分离小岛的分子和细胞分析.
- 评估胰岛素受体 (INSR) 和IGF1受体 (IGF1R) 的激活和信号.
- 在体内研究葡萄糖耐受性和β细胞增殖.
- 使用单克隆抗体来阻断受体-受体相互作用.
主要成果:
- 接受器淘汰的小鼠表现出严重的胰岛素血,低血糖和周围死亡率.
- 受体的丧失导致INSR-IGF1R激活,β细胞增殖和质量增加.
- 在成年小鼠中,诱导性β细胞特异性受体淘汰改善了葡萄糖耐受性和β细胞增殖.
- 接受器促进了INSR-IGF1R脱敏的克拉介导内细胞分裂.
- 阻断受体-受体相互作用维持了β细胞中的INSR-IGF1R激活.
结论:
- 接受器起到关键的负调节作用,保护胰腺β细胞免受构成性胰岛素和IGF1信号的侵害.
- 接收器保护β细胞免受过度激活,防止潜在的故障.
- Inceptor 是一个有前途的分子标,用于开发可使β细胞敏感并治疗糖尿病的疗法.
相关概念视频
Insulin: The Receptor and Signaling Pathways
2.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.0K
Glucagon-like Receptor Agonists
580
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
580
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.7K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.7K
Hormones Regulating Blood Glucose
5.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.6K
Insulin Secretory Vesicles
6.1K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
6.1K
Oral Hypoglycemic Agents: Glinides
407
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
407


